Zymeworks Inc. Banner Image

Zymeworks Inc. has reached its limit for free report views

Work for Zymeworks Inc.? Upgrade Your Profile and unlock all your annual reports.

Zymeworks Inc.

  • Ticker ZYME
    Exchange NYSE More
  • Industry Biotechnology More
  • Sector Healthcare More
Zymeworks Inc. Logo Image
  • 201-500 Employees
  • Based in Vancouver, British Columbia
Zymeworks (NYSE:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab (ZW25), is a novel AzymetricMore™ bispecific antibody currently in a registration-enabling clinical trial for refractory HER2+ biliary tract cancer as well as several Phase 2 clinical trials for HER2+ gastroesophageal and breast cancers. Zymeworks’ second clinical candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.
Zymeworks Inc.

Most Recent Annual Report

Zymeworks Inc.
MOST RECENT 2021 Annual Report and Form 10K

Report Locked. Zymeworks Inc. has reached its limit for free report views.

Older/Archived Annual Reports